Last updated on October 2020

Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ewing's Family Tumors | Cancer | Cancer (Pediatric) | Neoplasms | Cancer/Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Diagnosis of an advanced local or metastatic solid tumor
  • Adequate hematologic, hepatic, renal, and coagulation function

Exclusion Criteria:

  • Prior exposure to 225 mg/m2 of Dox HCl or DOXIL / CAELYX or 450 mg/m2 of epirubicin HCl.
  • CHF, severe myocardial insufficiency, or cardiac arrhythmia
  • Any of the following within 28 days prior to Cycle 1 Day 1:
  • Major surgery, as defined by the Investigator
  • Radiotherapy
  • Chemotherapy
  • Currently enrolled in or discontinued from a clinical study involving an investigational agent or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.